enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Ulixacaltamide - Wikipedia

   en.wikipedia.org/wiki/Ulixacaltamide

   Ulixacaltamide is an investigational new drug developed by Praxis Precision Medicines, designed to treat essential tremor, [1] a common neurological disorder characterized by involuntary rhythmic shaking. It functions as a selective inhibitor of T-type calcium channels, which are implicated in the abnormal neuronal activity associated with ...

3. Deep brain stimulation surgery developed in Chicago helps ...

   www.aol.com/deep-brain-stimulation-surgery...

   "The degree of tremor control is 90, 95 sometimes even 98 percent. So it's quite … it's almost like a miracle," Sani said. O'Brien began having tremors when he was just 4 years old.

4. Essential tremor - Wikipedia

   en.wikipedia.org/wiki/Essential_tremor

   Another invasive surgical treatment of essential tremor is deep brain stimulation (DBS). DBS is a surgical procedure that involves the placement of a permanent electrode with 4-8 contacts within the brain with connecting wires connected to a pulse stimulator implanted near the patient's collarbone. [68]

5. Deep brain stimulation - Wikipedia

   en.wikipedia.org/wiki/Deep_brain_stimulation

   DBS has been approved by the Food and Drug Administration as a treatment for essential and Parkinsonian tremor and since 1997, [3] and for Parkinson's disease (PD) since 2002. DBS was approved as humanitarian device exemptions for dystonia in 2003, [4] obsessive–compulsive disorder (OCD) in 2009, and approved for epilepsy in 2018.

6. Jazz Pharmaceuticals' tremor drug fails in mid-stage study - AOL

   www.aol.com/news/jazz-pharmaceuticals-tremor...

   The drug, called suvecaltamide, was being tested in adults with essential tremor, a condition that affects the nervous system and causes involuntary and rhythmic shaking, affecting about 10 ...

7. Biogen Terminates Collaboration With Sage Therapeutics For ...

   www.aol.com/biogen-terminates-collaboration-sage...

   The companies recently announced negative results from the Phase 2 KINETIC 2 Study of investigational SAGE-324 for the chronic treatment of essential tremor (ET) and discontinued further clinical ...